COMP <GO>
AMN vs ASTH // REVENUE GROWTH (YOY)
AMN Healthcare Services Inc (NYSE) VS. Astrana Health Inc. (NASDAQ) • 15-METRIC TALLY: AMN 4
— ASTH 6
▲ REVENUE GROWTH (YOY) LEADER: ASTH
LAST: $46.94 (+0.47%) • MKT CAP: $1.82B
revenue-growth
-8.50%
LAST: $36.62 (-0.14%) • MKT CAP: $1.82B
revenue-growth
56.40%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMN VS. ASTH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMN | ASTH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 28.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -7.20% | 4.60% | -11.80 | ASTH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 27.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 12.86% | 5.75% | +7.11 | AMN | /fcf-yield <GO> |
| Operating Margin | -2.00% | 2.50% | -4.50 | ASTH | /operating-margins <GO> |
| Net Profit Margin | -3.50% | 0.80% | -4.30 | ASTH | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | -8.50% | 56.40% | -64.90 | ASTH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.43% | -0.43 | ASTH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.76 | 2.54 | +0.22 | AMN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | ASTH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.9 | 46.7 | +29.19 | AMN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 63.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.82B | $1.82B | $1.5M | AMN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMN REV | ASTH REV | AMN GROSS % | ASTH GROSS % | AMN FCF | ASTH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.73B | $3.18B | 28.3% | — | $233.8M | $104.5M |
| FY 2024 | $2.98B | $2.03B | 30.8% | — | $239.5M | $44.2M |
| FY 2023 | $3.79B | $1.39B | — | — | $372.2M | $68.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMN // BETA —
ASTH // BETA —